NCT07335211招募中3 期
A Multicenter, Randomized, Single-blind, Active Controlled, Phase III Clinical Trial to Evaluate the Efficacy and Safety of HUC3-637 in Patients With Primary Open Angle Glaucoma or Ocular Hypertension
适应症
干预措施
试验速览
- 阶段
- 3 期
- 状态
- 招募中
- 入组人数
- 206
- 试验地点
- 1
- 主要终点
- Mean change in diurnal IOP
研究概览
简要总结
A multicenter, randomized, single-blind, active controlled, phase III clinical trial to evaluate the efficacy and safety of HUC3-637 in patients with primary open angle glaucoma or ocular hypertension
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Single (Investigator)
入排标准
- 年龄范围
- 19 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Adults aged 19 years and older
- •Participants diagnosed with POAG or OH
- •Have fully explained and understood the study and have voluntarily given written informed consent.
排除标准
- •Acute or chronic angle-closure glaucoma
- •Congenital glaucoma, secondary glaucoma (open-angle glaucoma)
研究组 & 干预措施
HUC3-637-R
Active Comparator
Dorzolamide, Timolol
干预措施: HUC3-637-R (Drug)
HUC3-637
Experimental
Dorzolamide, Timolol
干预措施: HUC3-637 (Drug)
结局指标
主要结局
Mean change in diurnal IOP
时间窗: 12 week
次要结局
未报告次要终点
研究者
研究点 (1)
Loading locations...
相似试验
招募中
3 期
The Efficacy and Safety of Inpegsomatropin Injection in Children With Short Stature Born Small for Gestational AgeSmall for Gestational AgeNCT07309562Xiamen Amoytop Biotech Co., Ltd.141
招募中
2 期
Firmonertinib Combined With Definitive Radiotherapy in Stage III Unresectable EGFR Uncommon Mutant Pulmonary AdenocarcinomaNCT07314216Hunan Cancer Hospital15
招募中
4 期
A Study of Teprotumumab N01 in Subjects With Active Thyroid Eye DiseaseThyroid Eye DiseaseNCT07265258Innovent Biologics (Suzhou) Co. Ltd.92
尚未招募
1 期
An Open-label, Single-arm, Prospective, Multicenter, Phase I/II Clinical Study on the Safety and Efficacy of CD19/BCMA CAR-T Cell Therapy for Relapsed/Refractory Warm Antibody Autoimmune Hemolytic AnemiaNCT07324889Yihao Wang24
招募中
3 期
A Phase III Study Comparing HRS-4357 With Novel Androgen Receptor Pathway Inhibitors in Patients With Progressive, PSMA-Positive Metastatic Castration-Resistant Prostate CancerNCT07311694Jiangsu HengRui Medicine Co., Ltd.370